In a report released yesterday, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Lexeo Therapeutics, Inc. (LXEO – Research Report), with a price target of $21.00. The company’s shares closed yesterday at $16.58.
According to TipRanks, Matteis is a 4-star analyst with an average return of 6.4% and a 45.45% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Neurogene, ACADIA Pharmaceuticals, and BioMarin Pharmaceutical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Lexeo Therapeutics, Inc. with a $21.33 average price target, representing a 28.65% upside. In a report released on March 11, RBC Capital also maintained a Buy rating on the stock with a $24.00 price target.
See today’s best-performing stocks on TipRanks >>
LXEO market cap is currently $386.1M and has a P/E ratio of -6.30.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Lexeo Therapeutics, Inc. (LXEO) Company Description:
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich’s ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Read More on LXEO:
- Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
- Lexeo Therapeutics price target raised to $24 from $22 at RBC Capital
- Lexeo Therapeutics’ Strategic $95M Share Placement and Financial Update
- Lexeo Therapeutics reports protein expression data from SUNRISE-FA trial
- Lexeo Therapeutics expects cash to fund operations into 2027
